Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

androgen receptor antagonist TQB3720

An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist TQB3720 specifically targets and binds to the AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AR antagonist TQB3720
Code name:	TQB 3720 TQB-3720 TQB3720

androgen receptor antagonist TQB3720

Search NCI's Drug Dictionary